ResearcherHumboldt-Universität zu BerlinNo recent work listed

Kaja Hoyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3195-6561; OpenAlex author ID A5032576736. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2021: 1 paper

Papers 1

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Co-author DOI 10.1016/j.ebiom.2021.103327 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Frédérik Damm · 1 shared paper, 2021 · strength 0.10
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327 ↗
Jana Käthe Striefler · 1 shared paper, 2021 · strength 0.10
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327 ↗
Philipp Lohneis · 1 shared paper, 2021 · strength 0.10
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327 ↗
Marianne Sinn · 1 shared paper, 2021 · strength 0.10
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327 ↗
Uwe Pelzer · 1 shared paper, 2021 · strength 0.10
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327 ↗
Hanno B. Riess · 1 shared paper, 2021 · strength 0.10
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.